Lesional pruritus in pyoderma gangrenosum: Present but not predominant Authors: Sarah L Becker, Richard Zhang, Emile Latour, Katelyn Downey, Jaclyn Roland-McGowan, Jordan Gillespie, Alex G Ortega-Loayza Published: 2026 ABSTRACT AbstractPyoderma gangrenosum (PG) is a rare dermatologic disease resulting in chronic, painful ulcerations, most commonly on the lower extremity. Pruritus is a common symptom in many dermatologic conditions but has not been thoroughly evaluated in patients with PG. We sought to characterize the prevalence, severity, and impact on QOL of lesional pruritus in patients with PG. Data were obtained from the “Pyoderma Gangrenosum Study” (IRB#16753) at Oregon Health and Science University. Standardized outcome data were prospectively collected during clinical encounters from December 2019 to May 2024. Inclusion criteria were adults who presented for at least 2 clinical visits and a PARACELSUS score ≥10. We analyzed data from 136 patients with 178 ulcers. At baseline, 69% of the patients reported moderate pruritus with a mean severity of 3.3 (0–10 scale, 95% confidence interval = 2.9–3.8), which decreased with healing (from 3.7 to 2.6). QOL scores (Skindex-Mini, Wound-QoL) improved in parallel with healing. Higher pruritus severity was associated with younger age and inflammatory arthritis, whereas analgesic use and systemic therapies showed no consistent associations. In summary, our findings suggest that lesional pruritus is a common symptom among patients with PG and significantly affects their QOL. These findings support routine assessment and antipruritic interventions in the management of PG.Keywords: Chronic wounds, Patient-reported outcomes, Pruritus, Pyoderma gangrenosum Introduction Pyoderma gangrenosum (PG) is a rare, autoinflammatory dermatosis that results in painful, disfiguring ulcers, which significantly impact QOL (Ighani et al, 2019; Nusbaum et al, 2024; Sanchez-Melendez et al, 2024). The significance of pruritus in PG is poorly understood, despite it being a common symptom experienced by patients with a variety of dermatologic conditions. Pruritus is known to negatively impact QOL and outcomes globally among dermatologic conditions and specifically in hidradenitis suppurativa, a chronic, inflammatory skin condition that, similar to PG, is part of the family of neutrophilic dermatoses (Kini et al, 2011; Montero-Vilchez et al, 2021; Trupiano et al, 2025). In addition, biologic treatment of PG has been shown to decrease pruritus as well as improve QOL, suggesting that pruritus likely contributes to decreased QOL in patients with PG (Flora et al, 2025). This study sought to characterize the prevalence, severity, and QOL burden of lesional pruritus in patients with PG. Results A total of 136 patients with 178 ulcers were included in the analysis (Table 1). At baseline, 69.1% of patients reported experiencing pruritus (95% confidence interval [CI] = 62.0–75.4%). The mean pruritus severity score was 3.3 (0–10 scale, 95% CI = 2.9–3.8) (Figure 1). Pruritus severity remained relatively stable from baseline (3.3, 95% CI = 2.9–3.8) to 6 months (3.0, 95% CI = 2.2–3.9). Among ulcers that healed, the mean pruritus severity decreased from 3.7 (95% CI = 2.7–4.7) at baseline to 2.6 (95% CI = 1.6–3.5) at healing (Figure 2). Skindex-Mini scores improved from 3.7 (95% CI = 3.2–4.3) to 1.9 (95% CI = 1.3–2.5), and Wound-QoL scores improved from 2.1 (95% CI = 1.8–2.4) to 1.0 (95% CI = 0.7–1.3) (Figure 2). Although pruritus severity and QOL both improved with ulcer healing, these changes were not statistically significant for either the Skindex-Mini (P = .758) or Wound-QoL Total (P = .237), suggesting that there was no evidence that the relationship between pruritus and QOL differed over time. Therefore, subsequent analyses treated the relationship between pruritus and QOL as stable across follow-up. Table 1Study Participant DemographicsCharacteristicsUlcers (n = 178)Age (y), mean (SD)55.6 (14.0)Male sex44 (24.7%)Race and ethnicity, n (%)Black1 (0.6%)Other23 (12.9%)Hispanic or Latino7 (3.9%)White147 (82.6%)Smoking statusCurrent40 (22.5%)Former46 (25.8%)Never86 (48.3%)Medical historyInflammatory bowel disease, n (%)29 (16.3%)Crohn’s disease19 (65.5%)Ulcerative colitis6 (20.7%)Arthritis, n (%)52 (29.2%)Venous insufficiency, n (%)32 (18.0%)Congestive heart failure, n (%)17 (9.6%)Solid organ cancer, n (%)25 (14.0%)Ulcer age (mo)Mean (SD)11.6 (17.1)Median (minimum–maximum)5.0 (0.0–96.0)Demographic information was collected for all participants. Race and ethnicity were collected to characterize the study population and to allow for assessment of potential differences in disease presentation and care across groups. These data were obtained from the electronic health record and are based on patient self-report at the time of clinical intake. Race and ethnicity categories reflect those recorded in the electronic health record; the “Other” category includes patients who self-identified with a race or ethnicity not otherwise represented. Categories are presented in alphabetical order. Study Participant Demographics Demographic information was collected for all participants. Race and ethnicity were collected to characterize the study population and to allow for assessment of potential differences in disease presentation and care across groups. These data were obtained from the electronic health record and are based on patient self-report at the time of clinical intake. Race and ethnicity categories reflect those recorded in the electronic health record; the “Other” category includes patients who self-identified with a race or ethnicity not otherwise represented. Categories are presented in alphabetical order. Mean baseline pruritus score. Among the 178 ulcers included in the analysis, the mean pruritus severity score based on AI-NRS over the past 7 days was 3.3, although values ranged from 0.0 to 10.0. This suggests that, on average, ulcers of patients with PG experience a mild-to-moderate degree of pruritus at baseline, although individual scores varied widely across the full scale. AI-NRS, average itch numeric rating scale; CI, confidence interval; PG, pyoderma gangrenosum. Trends in pruritus and QOL over time. Pruritus severity and impact on QOL (through Skindex-Mini and Wound-QoL scores) were assessed across clinical time points (baseline versus healed). Although a trend of decreased pruritus severity and improved QOL with ulcer healing was observed, this interaction was not statistically significant, for either the Skindex-Mini (P = .758) or Wound-QoL Total (P = .237), suggesting that the impact of pruritus on QOL was consistent over time. Linear mixed-effects models, adjusted for time point, showed that higher pruritus severity was significantly associated with worse QOL in patients with PG. For the Skindex-Mini, each 1-point increase in the pruritus score corresponded to a 0.14-point increase in the Skindex-Mini score (95% CI = 0.07–0.21; P < .001), reflecting worse dermatology-specific QOL. A similar pattern was observed in the Wound-QoL model, where each 1-point increase in the pruritus score corresponded to a 0.10-point increase in the Wound-QoL Total score (95% CI = 0.06–0.14; P < .001), indicating worse wound-related QOL. This association remained statistically significant in models adjusted for time point and when including a random intercept for patients to account for repeated measures, suggesting that pruritus has an independent and persistent impact on patient-reported outcomes. The relationship between pruritus severity and QOL was assessed among patients who had healed ulcers (n = 43). At the time of maximum pruritus severity, mean (SD) Skindex-Mini and Wound-QoL scores were 3.7 (1.9) and 2.0 (1.1), respectively. By the time of healing, both decreased (Skindex-Mini: mean [SD] = 1.9 [1.9]; Wound-QoL: mean [SD] = 1.0 [1.0]), reflecting improvements in QOL for patients who healed (Figure 3). Both correlation and regression analyses indicated no significant relationship between maximum pruritus severity and improvement in QOL scores. Correlations were weak and negative (Skindex-Mini: ρ = −0.14, 95% CI = −0.41 to 0.16; Wound-QoL Total: ρ = −0.15, 95% CI = −0.45 to 0.16), and regression models similarly showed no significant associations (Skindex-Mini: β = −0.12, 95% CI = −0.35 to 0.11; P = .309; Wound-QoL Total: β = −0.05, 95% CI = −0.17 to 0.07; P = .402). Overall, these results suggest that patients with higher peak pruritus scores did not consistently experience greater gains in QOL by the time of healing, indicating that the magnitude of improvement may be influenced by factors beyond initial pruritus severity. Change in Skindex-Mini and Wound-QoL scores from maximum pruritus score to healing. At the time of maximum pruritus severity, mean (SD) Skindex-Mini scores were 3.7 (1.9), and the mean (SD) Wound-QoL Total scores were 2.0 (1.1). By the time of healing, both scores had declined substantially (Skindex-Mini: 1.9 [1.9], Wound-QoL: 1.0 [1.0]), reflecting improvements in QOL across the cohort. Each gray bar represents an individual patient’s score trajectory. Large black points and error bars represent the mean and 95% confidence intervals at each time point. We also examined the correlation between pruritus severity (average itch numeric rating scale [AI-NRS] score) and pain severity (pain numeric rating scale [P-NRS] score, Skindex-Mini “hurting” symptom subscore, and Wound-QoL pain subscore) at both baseline and healed time points (Table 2). At baseline, pruritus and pain were moderately correlated (Spearman ρ = 0.29, 95% CI = 0.14–0.43, P < .001). Among patients with healed ulcers, the correlation remained positive and slightly stronger (ρ = 0.46, 95% CI = 0.14–0.70, P = .002), although the sample size was smaller (n = 43). These findings suggest that pruritus and pain are likely related symptoms but are not redundant measures. Table 2Relative Intensity of Pain Compared with PruritusMeasureNumber of PatientsMean (SD)Median (Minimum–Maximum)Itch NRS1783.3 (3.0)3.0 (0.0–10.0)Pain NRS1775.0 (3.0)5.0 (0.0–10.0)Skindex-Mini “Hurting” Subscore1774.1 (2.0)5.0 (0.0–6.0)Wound-QoL Pain Subscore1762.4 (1.3)2.5 (0.0–4.0)Mean pruritus score was compared with mean pain score across several different pain-related measures, including the pain NRS score, Skindex-Mini “hurting” symptom subscore, and the Wound-QoL pain item. Both pruritus and pain NRS scores reported average severity of the respective measure of the past 7 days on a 0–10 scale. Results are summarized with descriptive statistics.Abbreviation: NRS, numeric rating scale. Relative Intensity of Pain Compared with Pruritus Mean pruritus score was compared with mean pain score across several different pain-related measures, including the pain NRS score, Skindex-Mini “hurting” symptom subscore, and the Wound-QoL pain item. Both pruritus and pain NRS scores reported average severity of the respective measure of the past 7 days on a 0–10 scale. Results are summarized with descriptive statistics. Abbreviation: NRS, numeric rating scale. Baseline pruritus severity was compared betwee patients who reported the use of prescription pain medication and those who did not (Figure 4). The mean pruritus score was 3.5 (SD = 3.0) among those using prescription pain medication and 3.0 (SD = 3.0) among those not using medication. The use of prescription pain medication was not associated with higher baseline pruritus severity (P = .230, Wilcoxon rank-sum test). Pruritus severity is not associated with prescription pain medication use. Baseline pruritus severity was compared between patients who reported use of prescription pain medication and patients who did not. The mean score was 3.5 (SD = 3.0) in the prescription pain medication group and 3.0 (SD = 3.0) in the group without prescription pain medication use. There was no statistically significant difference in baseline pruritus severity between groups (P = .230), suggesting that prescription pain medication use was not associated with higher pruritus severity at baseline. We also assessed the association between pruritus severity and patient-reported treatment satisfaction over time (Figure 5). Pruritus severity was not associated with treatment satisfaction (OR = 0.96, 95% CI = 0.87–1.05, P = .351). Treatment satisfaction was significantly higher at healing than at baseline, with patients nearly 6 times more likely to report satisfaction at healing (OR = 5.86, 95% CI = 2.41–14.25, P < .001), although the wide CI indicates uncertainty in the precise magnitude of this effect. Patients were significantly more likely to report treatment satisfaction at 3 months (OR = 4.81, 95% CI = 2.38–9.73, P < .001) and at 6 months (OR = 2.64, 95% CI = 1.18–5.91, P = .018) than at baseline, with no difference at 12 months (OR = 0.79, 95% CI = 0.21–3.00, P = .728). These findings indicate that treatment satisfaction improved in the first 6 months of follow-up but that this improvement was not explained by changes in pruritus severity. Pruritus severity was also compared across PG subtypes; however, the small numbers within subtypes limited interpretation, and estimates should be considered descriptive (Table 3). Impact of pruritus severity on treatment satisfaction. Patient satisfaction with treatment was assessed over time as the proportion of patients reporting treatment satisfaction at baseline visit versus healed. Mean pruritus severity score was compared at each time point. Pruritus severity was not significantly associated with treatment satisfaction (OR = 0.96, 95% CI = 0.87–1.05, P = .351). However, treatment satisfaction was significantly higher at the time of healing than at baseline, with patients nearly 6 times more likely to report satisfaction at healing (OR = 5.86, 95% CI = 2.4114–.25, P < .001). CI, confidence interval. Table 3Pruritus severity by PG subtypePG SubtypeNumber of PatientsMean (SD)Median (Minimum–Maximum)Classic (ulcerative)1443.2 (3.1)3.0 (0.0–10.0)Peristomal223.6 (3.0)4.0 (0.0–10.0)Vegetative65.5 (1.8)5.0 (3.0–8.0)Bullous24.0 (5.7)4.0 (0.0–8.0)Superficial granulomatous31.0 (1.7)0.0 (0.0–3.0)Subcutaneous10.0 (NA)0.0 (0.0–0.0)Baseline pruritus severity was assessed by PG subtype. Small sample sizes in several subtypes precluded formal statistical testing. Results are summarized with descriptive statistics.Abbreviations: NA, not applicable; PG, pyoderma gangrenosum. Pruritus severity by PG subtype Baseline pruritus severity was assessed by PG subtype. Small sample sizes in several subtypes precluded formal statistical testing. Results are summarized with descriptive statistics. Abbreviations: NA, not applicable; PG, pyoderma gangrenosum. Pruritus severity was greater among younger patients (P < .001) and those with a history of inflammatory arthritis (P = .029). No consistent associations were observed between systemic therapies and pruritus improvement or between baseline pruritus severity and clinical factors such as PG subtype, ulcer age, infection, drainage, treatment, or comorbidities. Discussion Lesional pruritus is a common and clinically relevant symptom in patients with PG; nearly 70% report moderate pruritus at baseline. Pruritus and pain were positively correlated at baseline and remained positively correlated at healing, suggesting that they are related symptoms but not interchangeable. These findings reinforce the importance of addressing pruritus in addition to pain when implementing therapeutic interventions for PG. On average, pruritus severity was moderate at baseline and tended to improve as ulcers healed, although individual scores varied widely. Cross-sectional analysis showed that higher pruritus severity was associated with worse QOL, but longitudinal analysis found only weak, nonsignificant correlations between changes in pruritus scores and changes in QOL. However, although there was no association between maximum pruritus severity and QOL, there was an improvement in QOL with healing, which followed improvements in pruritus. Likewise, pruritus severity was not associated with treatment satisfaction, although satisfaction increased substantially with healing. Because higher peak pruritus scores did not consistently translate to greater improvements in QOL, this suggests that the presence rather than the severity of pruritus may play an important role in decreased QOL for patients with PG and that improvements in QOL may be influenced by factors beyond pruritus severity. Furthermore, although QOL scores improved with healing, reductions in pruritus were less consistent. This pattern may reflect a delayed or inconsistent response to therapies and barriers to treatment adherence. The lack of association between pruritus score and treatment satisfaction is difficult to interpret and could reflect inadequate treatment for pruritus in patients with PG. Treatment satisfaction decreased over time, which may reflect the cumulative burden of a persistent wound and ongoing medical needs rather than changes in pruritus severity. The lack of association between pruritus and prescription pain medication suggests that pruritus may operate through mechanisms distinct from those of pain (Yosipovitch et al, 2018). An alternative pathway triggering pruritus is also supported by the increased burden of pruritus observed in patients with a history of inflammatory arthritis, because it has been shown that patients with inflammatory arthritis have altered immune signaling and overlapping mechanisms with inflammatory pruritus (van Laarhoven et al, 2013). There is also evidence that IL-23 blockade and subsequent downregulation of proinflammatory genes and reduction in key inflammatory cytokines, including IL-8, IL-6, and TNF-α, lead to a decrease in pruritus (as well as pain and ulcer size), which suggests that persistent pruritus may be driven by ongoing inflammation, even when ulcers appear to be healing clinically (Flora et al, 2025). In addition, studies of chronic nodular prurigo and atopic dermatitis have revealed that neutrophils can initiate and maintain pruritus through CXCR3-dependent pathways (Walsh et al, 2019). The overexpression of CXCR3 in PG lesions has been documented, with significantly higher numbers of CXCR3-expressing cells than in healthy controls (Antiga et al, 2017). Given that PG is characterized by neutrophil-dominant inflammation and that neutrophils promote CXCL10 expression and subsequent activation of CXCR3 receptors on sensory neurons to induce pruritus, similar mechanisms may contribute to persistent pruritus in PG, although this has not been studied directly (Walsh et al, 2019). Limitations of this study include a modest sample size and a single-institution design. Because the cohort was drawn from a PG referral center, the baseline severity of pruritus may be higher than in the general PG population. The higher burden of pruritus observed among younger patients and those with inflammatory arthritis should be interpreted cautiously, because these findings were exploratory and based on univariable analyses. In addition, some subgroup analyses were based on small numbers, so those results should be considered descriptive. In summary, although pain is the dominant symptom among patients with PG, lesional pruritus is a common and burdensome symptom. While pruritus may not be a driver of disease burden compared with pain, it is an underrecognized symptom that contributes to an impaired QOL. Although pruritus and QOL tend to improve with healing, larger studies are needed to validate these findings and to clarify how topical and systemic therapies may best address pruritus in PG and other neutrophilic dermatoses. Materials and Methods Data were obtained from the “Pyoderma Gangrenosum Study” (IRB#16753) at Oregon Health and Science University. Standardized demographic, clinical, and patient-reported outcomes data were prospectively collected during clinical encounters from December 2019 to May 2024. Race and ethnicity were collected to characterize the study population and to allow for assessment of potential differences in disease presentation and care across groups. These data were obtained from the electronic health record and are based on patient self-report at the time of clinical intake. Inclusion criteria were adults who presented for at least 2 clinical visits with a PARACELSUS score ≥10 (Orfaly et al, 2022). Patient-reported pruritus severity was assessed using the AI-NRS (Yosipovitch et al, 2019). The AI-NRS is a single-item, patient-reported questionnaire that measures pruritus severity in the past week on a scale of 0–10 with the question “How itchy has your skin felt in the last 7 days?” (0–10 scale; AI-NRS 0 = no pruritus; AI-NRS <3 = mild pruritus; AI-NRS ≥3 to <7 = moderate pruritus; AI-NRS ≥7 to <9 = severe pruritus; and AI-NRS ≥9 = very severe pruritus). Pruritus scores reflect lesional pruritus rather than total body pruritus. Pain was similarly analyzed using the P-NRS, a single-item, patient-reported questionnaire, which asked about pain severity over the past 7 days (0–10 scale; P-NRS 0 = no pain; P-NRS <3 = mild pain; P-NRS ≥3 to <7 = moderate pain; P-NRS ≥7 to <9 = severe pain; and P-NRS ≥9 = very severe pain) (Erickson et al, 2023; Silverberg, 2021). Pain severity was further assessed using the Skindex-Mini “hurting” symptom subscore and Wound-QoL pain subscore (Janke et al, 2024; Swerlick et al, 2021). QOL outcomes were measured with the Skindex-Mini and Wound-QoL questionnaires (Janke et al, 2024; Swerlick et al, 2021). Pruritus, pain, and QOL outcomes were grouped by time point for analysis. Time points were selected on the basis of typical duration between visits and data availability (baseline, 3 months, 6 months, 12 months, and healed). Healed was a clinical definition defined by primary ulcer closure as assessed by a board-certified dermatologist specializing in PG. The primary endpoint was the severity of pruritus at baseline, as measured by the AI-NRS. The secondary endpoints were the prevalence of pruritus among patients with PG, pain severity compared with pruritus severity, the impact of pruritus on patient-reported QOL, the association between pruritus severity and prescription pain medication use, the association of pruritus severity with patient-reported treatment satisfaction, and pruritus severity among subtypes of PG. Exploratory analyses assessed clinical predictors of pruritus severity at baseline. Statistical analysis was conducted in R: A Language and Environment for Statistical Computing (Team, 2025). Average scores were reported as mean (95% CI). P < .05 was considered statistically significant. Continuous variables were summarized as means with 95% CIs, and categorical variables were summarized as counts and percentages. The baseline prevalence of pruritus was reported with binomial 95% CIs. Longitudinal associations between pruritus severity (0–10 NRS) and QOL outcomes (Skindex-Mini, Wound-QoL) were evaluated using linear mixed-effects models with a random intercept for patient to account for repeated measures (and the clustering of multiple ulcers within patients); fixed effects included time point and pruritus severity. Regression coefficients (β) with 95% CIs and Wald P-values are reported. Patient-reported treatment satisfaction was modeled with a generalized linear mixed model (logit link) that included a random intercept for patient and fixed effects for time point and pruritus severity; effects are presented as ORs with 95% CIs. Differences in baseline pruritus severity by prescription pain medication use were assessed using the Wilcoxon rank-sum test. For the healed-ulcer subgroup, within-patient change from the visit of maximum pruritus to the healing visit was summarized, and the relationship between maximum pruritus and change in QOL scores was examined using Spearman correlations and linear regression of change scores. Subtype analyses were descriptive only. All tests were 2 sided with α = 0.05. Analyses used available cases; no imputation was performed, and mixed-effects models used all available observations under a missing-at-random assumption. Ethics Statement This study was performed in accordance with the Declaration of Helsinki. The collection of human tissue samples for this study was approved as part of the study protocol. This human study was approved by the Oregon Health and Science University Institutional Review Board (#STUDY00016753). All adult participants provided written informed consent to participate in this study. Data Availability Statement The authors affirm that all data necessary for confirming the conclusions of the article are present within the article, figures, and tables. Original data generated in the preparation of this manuscript are available upon reasonable request to the corresponding author. ORCIDs Sarah L. Becker: http://orcid.org/0000-0003-1217-7359 Alex G. Ortega-Loayza: http://orcid.org/0000-0001-5028-9269 Emile Latour: http://orcid.org/0000-0002-7749-7217 Richard Zhang: http://orcid.org/0009-0006-0299-1057 Katelyn Downey: http://orcid.org/0000-0002-8782-4971 Jaclyn Roland-McGowan: http://orcid.org/0009-0005-0140-7237 Jordan Gillespie: http://orcid.org/0000-0002-8436-5626 Conflict of Interest AGO-L is the current President of the Pacific Dermatology Association and serves as an associate editor for Dermatology (Karger) and as an editorial board member of the American Journal of Clinical Dermatology. In addition, he is a consultant for Genentech and Guidepoint and an advisor to Bristol Myers Squibb, Boehringer Ingelheim, and Janssen. AGO-L has received research grants from Eli Lilly, Janssen, Incyte, and Pfizer. He is supported by National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases R01 AR083110. The remaining authors state no conflict of interest. Acknowledgments Institutional funds were used to cover the research, authors' time, administrative support, and publishing costs. Author Contributions Conceptualization: AGO-L; Data Curation: SLB, KD, RZ, JR-M, JG; Formal Analysis: EL; Funding Acquisition: AGO-L; Investigation: AGO-L, SLB, KD, JR-M, JG; Methodology: AGO-L; Project Administration: AGO-L; Resources: AGO-L; Supervision: AGO-L; Validation: EL; Visualization: EL; Writing – Original Draft Preparation: SLB, AGO-L; Writing - Review and Editing: AGO-L, SLB, EL, RZ, KD, JR-M, JG. Declaration of Generative Artificial Intelligence (AI) or Large Language Models (LLMs) The author(s) did not use AI/LLM in any part of the research process and/or manuscript preparation. accepted manuscript published online XXX; corrected proof published online XXX Footnotes Cite this article as: JID Innovations 2026;X:100500 References Associated Data Data Availability Statement The authors affirm that all data necessary for confirming the conclusions of the article are present within the article, figures, and tables. Original data generated in the preparation of this manuscript are available upon reasonable request to the corresponding author.